Murdock Hunter R. 4

4 · Axsome Therapeutics, Inc. · Filed Jun 18, 2025

Form 4

Period: 2025-06-16

General Counsel

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2025-06-17−7,500→ 37,383 total
Exercise: $29.91From: 2023-03-04Exp: 2032-03-04→ Common Stock (7,500 underlying)
Sale
Common Stock
2025-06-16$102.42/sh−7,500$768,150→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-18−7,500→ 29,883 total
Exercise: $29.91From: 2023-03-04Exp: 2032-03-04→ Common Stock (7,500 underlying)
Exercise/Conversion
Common Stock
2025-06-16$29.91/sh+7,500$224,325→ 7,500 total
Sale
Common Stock
2025-06-17$100.26/sh−7,500$751,950→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-16−7,500→ 44,883 total
Exercise: $29.91From: 2023-03-04Exp: 2032-03-04→ Common Stock (7,500 underlying)
Sale
Common Stock
2025-06-18$100.90/sh−7,500$756,750→ 0 total
Exercise/Conversion
Common Stock
2025-06-18$29.91/sh+7,500$224,325→ 7,500 total
Exercise/Conversion
Common Stock
2025-06-17$29.91/sh+7,500$224,325→ 7,500 total

Footnotes (5)

[F1]Such transaction was pursuant to a pre-approved 10b5-1 plan.
[F2]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
[F3]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $101.01 and $104.09
[F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $100.00 and $101.53.
[F5]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $100.00 and $101.96.

Documents

1 file